Publication

Fibroblast Growth Factor 23 and Mortality in Patients With Type 2 Diabetes and Normal or Mildly Impaired Kidney Function

Yeung, S. M. H., Binnenmars, S. H., Gant, C. M., Navis, G., Gansevoort, R. T., Bakker, S. J. L., de Borst, M. & Laverman, G. D., Nov-2019, In : Diabetes Care. 42, 11, p. 2151-2153 3 p.

Research output: Contribution to journalArticleAcademicpeer-review

Copy link to clipboard

Documents

  • Fibroblast Growth Factor 23 and Mortality in Patients With Type 2 Diabetes and Normal or Mildly Impaired Kidney Function

    Final publisher's version, 535 KB, PDF document

    Request copy

DOI

OBJECTIVE To study whether fibroblast growth factor 23 (FGF23) is associated with adverse outcomes in patients with type 2 diabetes and normal or mildly impaired kidney function. RESEARCH DESIGN AND METHODS We analyzed C-terminal FGF23 levels in 310 patients with type 2 diabetes and estimated glomerular filtration rate >= 60 mL/min/1.73 m(2). Associations of FGF23 with all-cause mortality and major adverse cardiovascular events (MACE) were studied by Cox regression. RESULTS During a follow-up of 5.8 years (3.3-6.5), 47 patients developed MACE and 28 patients died. FGF23 was associated with an increased risk of all-cause mortality (age- and sex-adjusted hazard ratio 2.78 [95% CI 1.76-4.40]) and MACE (1.67 [1.12-2.49]). Results were similar after additional adjustment for other potential confounders and were consistent upon replication in an independent cohort. CONCLUSIONS In patients with type 2 diabetes and normal or mildly impaired kidney function, FGF23 is associated with an increased risk of cardiovascular events and mortality.

Original languageEnglish
Pages (from-to)2151-2153
Number of pages3
JournalDiabetes Care
Volume42
Issue number11
Early online date5-Sep-2019
Publication statusPublished - Nov-2019

    Keywords

  • DISEASE, BONE

ID: 95173326